Prevnar 13 revenue trends
In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis. In 2016, Prevnar 13 revenues for adult indications witnessed a modest decline due to the high capture rate in eligible adult patients in the US in 2015 after its successful launch in 4Q14, which consequentially led to a decrease in its “catch up” opportunity in 2016.
In 1Q17, Prevnar 13 generated revenues of ~$1.4 billion, which reflected a ~8% YoY fall and 2% QoQ (quarter-over-quarter) fall. Prevnar 13 revenues for the adult indication continued to decline. In 2016, the FSME-IMMUN-TicoVac vaccine contributed ~$144 million to Pfizer’s net revenues.
About Prevnar 13
Prevnar 13 is indicated in adults above 18 years of age for the active immunization and prophylaxis against pneumonia and invasive disease caused by thirteen different strains of Streptococcus pneumonia. The vaccine provides immunization against S. pneumoniae strains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
The vaccine is also indicated for children between age six weeks to five years for active immunization and the prevention of invasive diseases caused by different serotypes of S. pneumoniae.
Pfizer’s peers in the vaccine market include GlaxoSmithKline (GSK), Merck (MRK), Sanofi (SNY), and Emergent BioSolutions. Notably, the Vanguard S&P 500 ETF (VOO) has ~1.14% of its total portfolio holdings in Pfizer.